Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-20

FDA Approved: JENTADUETO XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

FDA approved a supplemental application for JENTADUETO XR (linagliptin and metformin hydrochloride) by Boehringer Ingelheim Pharmaceuticals, Inc. This action re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • JENTADUETO XR (Linagliptin and metformin hydrochloride)

Snippet

SUPPL AP for JENTADUETO XR (LINAGLIPTIN AND METFORMIN HYDROCHLORIDE)